



IFW

PATENT
ATTORNEY DOCKET NO. 01948/088004

Certificate of Mailing: Date of Deposit: Oct 25, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathy Kirby

Printed name of person mailing correspondence

Kathy Kirby

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Karumanchi et al.

Confirmation No.: 6646

Serial No.: 10/624,809

Art Unit: 1647

Filed: July 21, 2003

Examiner: Ian D. Dang

Customer No.: 21559

Title: METHODS OF DIAGNOSING AND TREATING PRE-ECLAMPSIA OR
ECLAMPSIA

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: October 25, 2006

Kristina B. Brady
Kristina B. Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

Kimeya F. Harris, Ph.D.
Reg. No. 57,172

Sheet 1 of 1

| | | |
|---|----------------------------|-------------------|
| SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b)) | Attorney Docket No. | 01948/088004 |
| | Serial No. | 10/624,809 |
| | Applicant | Karumanchi et al. |
| | Filing Date | July 21, 2003 |
| | Group | 1647 |
| | IDS Filed | October 25, 2006 |

| U.S. PATENT DOCUMENTS | | | | | | |
|---|--|---------------------------|--------------------------|-------|----------|------------------------------|
| Examiner's Initials | Document Number | Issue or Publication Date | Patentee or Applicant | Class | Subclass | Filing Date (If Appropriate) |
| | 2006/0183175 | August 17, 2006 | Buhimschi et al. | | | |
| | | | | | | |
| | | | | | | |
| FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION | | | | | | |
| Examiner's Initials | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation (Yes/No) |
| | WO 2006/069373 | June 29, 2006 | WIPO | | | |
| | | | | | | |
| OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) | | | | | | |
| | Del-Sorbo et al., "The Synthesis of Platelet-Activating Factor Modulates Chemotaxis of Monocytes Induced by HIV-1 Tat," <i>Eur. J. Immunol.</i> 29:1513-1521 (1999). | | | | | |
| | Gordon et al., "Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients with Advanced Cancer," <i>J. Clin. Oncol.</i> 19:843-850 (2001). | | | | | |
| | Hunter et al., "Serum Levels of Vascular Endothelial Growth Factor in Preeclamptic and Normotensive Pregnancy," <i>Hypertension</i> 36:965-969 (2000). | | | | | |
| | Margolin et al., "Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination with Chemotherapy in Patients with Advanced Cancer: Pharmacologic and Long-Term Safety Data," <i>J. Clin. Oncol.</i> 19:851-856 (2001). | | | | | |
| | Sugimoto et al., "Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria," <i>J. Biol. Chem.</i> 278:12605-12608 (2003). | | | | | |

| | |
|---|------------------------|
| EXAMINER | DATE CONSIDERED |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. | |